AWM Investment Company’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

AWM Investment Company’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-20,000	Closed	-$2.83M	–	131
2021 Q2	$2.83M	Hold	20,000	–	–	0.28%	84
2021 Q1	$1.99M	Hold	20,000	–	–	0.22%	84
2020 Q4	$2.47M	Hold	20,000	–	–	0.31%	71
2020 Q3	$1.95M	Sell	20,000 -40,000	-67%	-$5M	0.32%	68
2020 Q2	$9.36M	Hold	60,000	–	–	1.64%	26
2020 Q1	$8.66M	Sell	60,000 -15,000	-20%	-$2.9M	2.3%	18
2019 Q4	$15.3M	Hold	75,000	–	–	3%	9
2019 Q3	$6.02M	Hold	75,000	–	–	1.28%	32
2019 Q2	$7.08M	Hold	75,000	–	–	1.35%	30
2019 Q1	$6.41M	Hold	75,000	–	–	1.26%	33
2018 Q4	$4.21M	Buy	75,000 +5,000	+7%	+$305K	0.92%	41
2018 Q3	$5.72M	Hold	70,000	–	–	0.95%	38
2018 Q2	$2.45M	Buy	70,000 +5,000	+8%	+$152K	0.41%	64
2018 Q1	$1.33M	Buy	65,000 +17,071	+36%	+$439K	0.26%	75
2017 Q4	$1.36M	Sell	47,929 -111,736	-70%	-$3.12M	0.26%	77
2017 Q3	$4.97M	Buy	+159,665	New	+$4.8M	0.87%	34

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

AWM Investment Company's RETA Position: Q3 2021 in Review

AWM Investment Company sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2021, closing a stake of 20,000 shares — an estimated $2.83M sold.

AWM Investment Company first reported a position in RETA in Q3 2017 and held it in 16 quarters. The position peaked at $15.3M in Q4 2019. 181 funds tracked by Wall St. Rank hold RETA as of Q3 2021.

AWM Investment Company reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2021 after selling out during the quarter.
AWM Investment Company sold 20,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2021, an estimated $2.83M.
AWM Investment Company first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 16 quarters.
AWM Investment Company's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $15.3M in Q4 2019.
181 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2021.

Based on AWM Investment Company's 13F filing for Q3 2021, filed 15 Nov 2021.